US Patent

US9242986 — Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates

Composition of Matter · Assigned to Shionogi and Co Ltd · Expires 2029-12-08 · 4y remaining

Vulnerability score 18/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a synthesis approach for carbamoylpyridone HIV integrase inhibitors and their intermediates.

USPTO Abstract

A synthesis approach providing an early ring attachment via a bromination to compound 1-1 yielding compound II-II, whereby a final product such as AA can be synthesized. In particular, the 2,4-difluorophenyl-containing sidechain is attached before creation of the additional ring Q.

Drugs covered by this patent

Patent Metadata

Patent number: US9242986
Jurisdiction: US
Classification: Composition of Matter
Expires: 2029-12-08
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Shionogi and Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.